New progress of chimeric antigen receptor T cells in the treatment of multiple myeloma

doi:10.3877/cma.j.issn.1674-3903.2023.05.010

Abstract

Abstract:

Multiple myeloma (MM) is a kind of malignant tumor of plasma cells, ranking as the second most common hematological malignancy, and has no cure. Despite the introduction of new drugs, the challenge of drug resistance and disease relapse in MM remains a primary focus of research, highlighting the urgent need for improved treatment options. Chimeric antigen receptor T cells (CAR-T) therapy is a new promising approach in recent years, which brings hope for curing of MM. This paper summarizes the advancements of CAR-T therapy in the treatment of MM, covering the aspects of clinical efficacy, safety and accessibility, with the aim of optimizing the treatment strategy.

Key words: Multiple myeloma, Chimeric antigen receptor T cells, Target selection, Adverse reaction

Yu Chen, Liangshun You, Haitao Meng, Min Yang. New progress of chimeric antigen receptor T cells in the treatment of multiple myeloma[J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 313-320.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2023.05.010

https://zhyzzz.cma-cmc.com.cn/EN/Y2023/V17/I05/313

References 73

1	Kane SF. Bone tumors: multiple myeloma[J]. FP Essent, 2020，493：30-35.
2	Cowan AJ, Tuazon SA, Poruguese AJ, et al. Chimeric antigen receptor T Cells for multiple myeloma：The journey so far and the road ahead[J]. Cancer J, 2021，27(2)：112-118.
3	Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century[J]. Blood Cancer J, 2020, 10(5): 56.
4	Choi T, Kang Y. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma[J]. Pharmacol Ther, 2022, 232: 108007.
5	中国医师协会血液科医师分会，中华医学会血液学分会．嵌合抗原受体T细胞治疗多发性骨髓瘤中国血液临床专家共识(2022年版)[J]．中华血液学杂志，2022, 43(4)：265-271.
6	Song EZ, Milone MC. Pharmacology of chimeric antigen receptor-modified T cells[J]. Annu Rev Pharmacol Toxicol, 2021，61：805-829.
7	Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J]. Proc Natl Acad Sci U S A, 1989，86(24)：10024-10028.
8	Stock S, Schmitt M, Sellner L. Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy[J]. Int J Mol Sci, 2019，20(24)：6223.
9	Liu Q, Li J, Zheng H, et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T[J]. Mol Cancer, 2023, 22(1)：28.
10	Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy[J]. J Hematol Oncol, 2023, 16(1)：97.
11	Sun W, Liang AB, Huang H, et al. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience[J]. Haematologica, 2023，108(8)：2011-2028.
12	Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study[J]. Lancet, 2020, 396(10254): 839-852.
13	Pan J, Yang JF, Deng BP, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients[J]. Leukemia, 2017, 31(12)：2587-2593.
14	Zhang X, Lu XA, Yang J, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features[J]. Blood Adv, 2020, 4(10): 2325-2338.
15	AnagnostouT, RiazIB, HashmiSK, et al. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis[J]. Lancet Haematol, 2020, 7(11): e816-e826.
16	Pasvolsky O, Kebriaei P, Shah BD, et al. Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead[J]. Blood Adv, 2023, 7(14)：3350-3360.
17	Lin MJ, Svensson-Arvelund J, Lubitz GS, et al. Cancer vaccines: the next immunotherapy frontier[J]. Nat Cancer, 2022, 3(8)：911-926.
18	Padda J, Khalid K, Zubair U, et al. Chimeric antigen receptor T cell therapy and its significance in multiple myeloma[J]. Cureus, 2021，13(6): e15917.
19	Kegyes D, Constantinescu C, Vrancken L, et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient？[J]. J Hematol Oncol, 2022，15(1)：78.
20	Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma-a promising key to therapy[J]. J Clin Med, 2021, 10(18)：4088.
21	Baker DJ, Arany Z, Baur JA, et al. CAR T therapy beyond cancer: the evolution of a living drug[J]. Nature, 2023, 619(7971)：707-715.
22	Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B- cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma[J]. Blood, 2016, 128(13)：1688-1700.
23	Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma[J]. J Clin Oncol, 2018，36(22)：2267-2280.
24	Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma[J]. J Clin Invest, 2019, 129(6): 2210-2221.
25	Roex G, Timmers M, Wouters K, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma[J]. J Hematol Oncol, 2020, 13(1)：164.
26	Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma[J]. N Engl J Med, 2019，380(18)：1726-1737.
27	Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma[J]. N Engl J Med, 2021，384(8)：705-716.
28	Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma[J]. N Engl J Med, 2023，388(11)：1002-1014.
29	Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CAR-TITUDE-1): a phase 1b/2 open-label study[J]. Lancet，2021，398(10297)：314-324.
30	Cohen AD, Mateos MV, Cohen YC, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents[J]. Blood, 2023，141(3)：219-230.
31	Mi JQ, Zhao W, Jing H, et al. Phase Ⅱ，open-label study of ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor-t-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CAR-TIFAN-1) [J]. J Clin Oncol, 2023，41(6)：1275-1284.
32	Holstein SA, Grant SJ, Wildes TM. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future[J]. J Clin Oncol, 2023，41(27)：4416-4429.
33	Xu J, Melenhorst JJ. CT103A, a forward step in multiple myeloma immunotherapies[J]. Blood Sci, 2021，3(2)：59-61.
34	Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma[J]. Blood, 2021，137(21)：2890-2901.
35	Li CR, Wang D, Song YP, et al. CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1)[J]. J Clin Oncol, 41(16 suppl): 8025
36	Oliver-Caldés A, González-Calle V, Cabañas V, et al. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CAR-TBCMA-HCB-01): a single-arm, multicentre, academic pilot study[J]. Lancet Oncol, 2023，24(8)：913-924.
37	Han X, Wang Y, Wei J, et al. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy[J]. J Hematol Oncol. 2019，12(1)：128.
38	Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma[J]. Nat Commun, 2020，11(1)：2283.
39	Wang Y, Cao J, Gu W, et al. Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma[J]. J Clin Oncol, 2022，40(20)：2246-2256.
40	Mei H, Li C, Jiang H, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma[J]. J Hematol Oncol, 2021，14(1)：161.
41	Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells[J]. Sci Transl Med, 2019, 11(485): eaau7746.
42	Pillarisetti K, Edavettal S, Mendonça M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma[J]. Blood, 2020, 135(15): 1232-1243.
43	Mailankody S, Devlin SM, Landa J, et al. GPRC5D-targeted CAR T cells for myeloma[J]. N Engl J Med, 2022，387(13)：1196-1206.
44	Xia J, Li H, Yan Z, et al. Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase Ⅱ Trial[J]. J Clin Oncol, 2023，41(14)：2583-2593.
45	Zhang M, Wei G, Zhou L, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial[J]. Lancet Haematol, 2023，10(2): e107-e116.
46	Li J, Stagg NJ, Johnston J, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing[J]. Cancer Cell, 2017，31(3)：383-395.
47	Jiang D, Huang H, Qin H, et al. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma[J]. Nat Commun, 2023，14(1)：3642.
48	Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far[J]. Nat Rev Clin Oncol, 2023，20(6)：359-371.
49	Strassl I, Schreder M, Steiner N, et al. The agony of choice-where to place the wave of BCMA-targeted therapies in the multiple myeloma treatment puzzle in 2022 and beyond[J]. Cancers (Basel), 2021，13(18)：4701.
50	Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies[J]. Blood Cancer J, 2021，11(4)：69.
51	Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management[J]. Blood Rev, 2019，34：45-55.
52	Da Vià MC, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma[J]. Nat Med, 2021, 27(4): 616-619.
53	Wong DP, Roy NK, Zhang K, et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers[J]. Nat Commun, 2022，13(1)：217.
54	Xie B, Li Z, Zhou J, et al. Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies[J]. Cancers (Basel)，2022, 14(13): 3230.
55	Choi BD, Yu X, Castano AP, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity[J]. Nat Biotechnol, 2019，37(9)：1049-1058.
56	Tousley AM, Rotiroti MC, Labanieh L, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells[J]. Nature, 2023，615(7952)：507-516.
57	Li W, Zhang B, Cao W, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing[J]. Exp Hematol Oncol, 2023，12(1)：44.
58	Pietrobon V, Todd LA, Goswami A, et al. Improving CAR T-cell persistence[J]. Int J Mol Sci, 2021, 22(19)：10828.
59	Wu L, Brzostek J, Sakthi Vale PD, et al. CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance[J]. Cell Rep Med, 2023，4(2)：100917.
60	Roddie C, O′Reilly M, Dias Alves Pinto J, et al. Manufacturing chimeric antigen receptor T cells: issues and challenges[J]. Cytotherapy, 2019，21(3)：327-340.
61	Li X, Dai H, Li X, et al. Optimal model establishment of whole-process management data for CAR-T therapy in China-how should this be done？[J]. Cell Mol Immunol, 2022，19(1)：122-124.
62	Levine BL, Miskin J, Wonnacott K, et al. Global manufacturing of CAR T cell therapy[J]. Mol Ther Methods Clin Dev, 2016，4：92-101.
63	Tyagarajan S, Spencer T, Smith J. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials[J]. Mol Ther Methods Clin Dev, 2019, 16：136-144.
64	Smith TT, Stephan SB, Moffett HF, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers[J]. Nat Nanotechnol, 2017，12(8)：813-820.
65	Ghassemi S, Durgin JS, Nunez-Cruz S, et al. Rapid manufacturing of non-activated potent CAR T cells[J]. Nat Biomed Eng, 2022, 6(2)：118-128.
66	Wong DP, Roy NK, Zhang K, et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers[J]. Nat Commun, 2022, 13(1)：217.
67	Rurik JG, Tombácz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury [J] Science, 2022，375(6576)：91-96.
68	Zhang J, Hu Y, Yang J, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL[J]. Nature, 2022, 609(7926)：369-374.
69	Agarwalla P, Ogunnaike EA, Ahn S, et al. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells[J]. Nat Biotechnol, 2022，40(8)：1250-1258.
70	Zhang DKY, Adu-Berchie K, Iyer S, et al. Enhancing CAR-T cell functionality in a patient-specific manner[J]. Nat Commun, 2023, 14(1)：506.
71	Wu JF, Dhakal B. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting[J]. J Hematol Oncol, 2023, 16(1)：86.
72	Muthuvel M, Srinivasan H, Louis L, et al. Engineering off-the-shelf universal CAR T cells: a silver lining in the cloud[J]. Cytokine, 2022，156：155920.
73	Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results[J]. Nat Med，2023, 29(2)：422-429.

[1]	Luyue Ding, Wei Liu, Ang Wei, Ruidong Zhang, Tianyou Wang, Linlin Liu, Buolun Zang, Yafeng Wang, Xianliang Wang. Clinical observation of blinatumomabin in the treatment of children with relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(02): 194-201.
[2]	Bingtong Lu, Yingrong Hou, Yongqiang Hu, Yaxin Qi. Clinical analysis of serum lactate dehydrogenase, interleukin-6, procalcitonin and high-sensitivity C-reactive protein levels in evaluating the prognosis of multiple myeloma patients with bacterial infection [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(03): 187-193.
[3]	Zhiwei Li, Qi Xiang, Shengnan Peng, Ling Guo, Jiangen Sun, Chuan Yang. Application of dexmedetomidine versus tramadol combined with ropivacaine in the radical operation of colon cancer under general anesthesia [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(03): 182-185.
[4]	Colorectal Cancer Committee of Chinese Medical Doctor Association, Colorectal Cancer Professional Committee of Chinese Anti-Cancer Association, Expert Committee on Quality Control of Colorectal Cancer of Center National Cancer/National Cancer Quality Control Center. Chinese expert consensus on targeted therapy for colorectal cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(01): 1-8.
[5]	Tao Chen, Hong Luo, JingJun Zhou. Risk factors of acute adverse reactions in elderly patients with esophageal cancer treated with radiotherapy alone and concurrent radiotherapy and chemotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 405-407.
[6]	Yuan Ji, Bajin Wei. Review of research progress on the role of NLRP3 inflammasome in the pathogenesis of adverse reactions of organ transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 308-312.
[7]	Yanqun Zhou, Peng Chen, Zenghui Liu, Jingjing Mao, Yaohe Li. Screening and verifying key genes and signal pathways involved in senescence of bone marrow mesenchymal stem cells in patients with multiple myeloma based on bioinformatics analysis [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2022, 12(05): 274-281.
[8]	Jingfang Lv, Haiyang Huang, Enrui Liu, Meng Zhuang, Xishan Wang. Application of PD-1 pathway blockage in the treatment of colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(01): 70-74.
[9]	Colorectal Cancer Committee of Chinese Medical Doctor Association, Colorectal Cancer Professional Committee of Chinese Anti-Cancer Association, Expert Committee on Quality Control of Colorectal Cancer of Center National Cancer/National Cancer Quality Control Center. Chinese expert consensus on targeted therapy for colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(05): 353-360.
[10]	Lijiao Jiang, Feng Zhang, Yuping Zhou. Clinical efficacy observation of treating elderly patients with acute non-variceal upper gastrointestinal hemorrhage using the MDT model [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 520-524.
[11]	Jun Dong, Fangfang Wu. Clinical efficacy and safety analysis of mFOLFOX6 and FOLFOX4 chemotherapy regimens in the treatment of rectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 236-240.
[12]	Xiaodong Yu, Dehua Li, Shan Gao, Xin Xu. Clinical observation on the treatment of mild active Crohn′s disease by combining Jiawei Lizhong Decoction with mesalazine [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 199-202.
[13]	Mengzhen Liu. Effect of psychological counseling on emotion and success rate of patients undergoing electronic gastroscopy for the first time [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(05): 317-319.
[14]	Hao Wang, Qianwen Ming, Bin Wang, Taikun Lu, Haining Zhang. Clinical diagnostic characteristics of linezolid-induced black hairy tongue [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(04): 254-260.
[15]	Anqi Liao, Mei Wang, Yuanquan Liao. Clinical diagnostic characteristics of Dapagliflozin-induced hematuria in a diabetic patient [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(03): 169-172.

Please choose a citation manager

Content to export